Abstract | BACKGROUND: METHODS:
Prostate cancer was induced in male Copenhagen rats by either subcutaneous or orthotopic implantation of R3327-MatLyLu cells. During the development of the tumor, plasma MMP-2, and MMP-9 were measured by gelatin-substrate zymography and Western blot technique with densitometry in untreated animals, rats treated with laser- induced hyperthermia, or with the new synthetic MMP inhibitor RO 28-2653. RESULTS: Normal prostatic tissue of the Copenhagen rats predominantly expressed proMMP-2 but not proMMP-9 whereas MMP-9 was only found in cancerous tissue. Elevated plasma MMP-9 values were demonstrated in rats with subcutaneous or orthotopic tumors. Animals with tumors and treated with the MMP inhibitor RO 28-2653 had both a lower tumor volume and a lower plasma MMP-9 concentration compared with controls. CONCLUSIONS: The determination of plasma MMP-9 in Dunning tumor rats is a useful tool to monitor the progression of prostate cancer and to assess the efficacy of drugs like MMP inhibitors or other treatment protocols.
|
Authors | Klaus Jung, Hans-Willi Krell, Bernhard Ortel, Tayyaba Hasan, Andreas Römer, Dietmar Schnorr, Stefan A Loening, Michael Lein |
Journal | The Prostate
(Prostate)
Vol. 54
Issue 3
Pg. 206-11
(Feb 15 2003)
ISSN: 0270-4137 [Print] United States |
PMID | 12518325
(Publication Type: Journal Article)
|
Copyright | Copyright 2002 Wiley-Liss, Inc. |
Chemical References |
- Biomarkers
- Biomarkers, Tumor
- Enzyme Inhibitors
- Matrix Metalloproteinase Inhibitors
- Piperazines
- Pyrimidines
- Ro 28-2653
- Matrix Metalloproteinase 2
- Matrix Metalloproteinase 9
|
Topics |
- Animals
- Biomarkers
- Biomarkers, Tumor
(blood)
- Disease Progression
- Enzyme Inhibitors
(pharmacology)
- Male
- Matrix Metalloproteinase 2
(blood)
- Matrix Metalloproteinase 9
(blood)
- Matrix Metalloproteinase Inhibitors
- Piperazines
(pharmacology)
- Prostatic Neoplasms
(blood, diagnosis)
- Pyrimidines
(pharmacology)
- Rats
- Rats, Inbred Strains
|